Ms. Heather Medwick reports

CYTOPHAGE EXPANDS COMMERCIALIZATION OF PHAGE PRODUCTS IN ASIAN POULTRY MARKET

Cytophage Technologies Ltd. has signed of a letter of intent (LOI) with a leading Pan-Asian industrial agrifood company headquartered in Singapore.

The LOI outlines a collaboration pathway between Cytophage and this company that operates in six countries and derives approximately 80 per cent of its multibillion-dollar revenue from poultry operations. "Fully integrated poultry producers provide multifaceted opportunities for phage products -- from eggs to feed to the chickens -- creating an exciting environment in which to have our phage products improve production numbers by decreasing bacterial loads," commented Cytophage chief executive officer Dr. Steven Theriault. Cytophage anticipates conducting trials with this commercial partner in Q4 of 2024.

Cytophage continues to collaborate with its distribution partner in Bangladesh, recently introducing its innovative lyophilized tablet designed to replace the traditional liquid form commonly used in phage therapy.

This new form is expected to increase product shelf life and product reliability in tropical zones.

The company recognizes the importance of regionalizing phage products to address local bacterial strains and environmental conditions in order to maximize product adoption and meet customer needs.

Cytophage also announces the departure of chief commercialization officer (CCO) Michael Graham to pursue other endeavours. The recently established commercialization committee of the board, together with Dr. Theriault and the commercialization team, will work to drive initiatives forward and expand Cytophage's market presence. "We will continue to explore and secure new commercialization opportunities in various marketplaces," stated Dr. Theriault. "Our thanks go to Michael for his contributions in advancing the company over the past six years and we wish him all the best for his future."

Cytophage will hold its annual general meeting (AGM) on June 25, 2024. The AGM materials can be found on the Cytophage website. This meeting will cover the business of the AGM. An investor presentation and update will be held at a later date.

About Cytophage Technologies Ltd.

Cytophage Technologies is a pioneering biotechnology company dedicated to bacteriophage research, product development and commercialization. Committed to addressing the global challenge of antibiotic resistance, Cytophage advances innovative products that harness the power of bacteriophages to combat bacterial infections affecting human health, animal health and food security.

We seek Safe Harbor.